<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444492</url>
  </required_header>
  <id_info>
    <org_study_id>CoRaLaII</org_study_id>
    <nct_id>NCT04444492</nct_id>
  </id_info>
  <brief_title>Combination of Ranibizumab and Targeted Laser Photocoagulation</brief_title>
  <acronym>CoRaLaII</acronym>
  <official_title>Long-term Need of Ranibizumab Injections With or Without Early Targeted Peripheral Laser Photocoagulation for Treatment of Macular Edema Due to Central Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravitreal injections of Ranibizumab will be applied in all patients according to treatment&#xD;
      guidelines. The experimental group will receive additional targeted laser photocoagulation of&#xD;
      the peripheral areas of capillary non-perfusion (up to 4 laser treatments within 1st year of&#xD;
      the study). Based on the long-term observation after CoRaLa I study an importantly shorter&#xD;
      duration of treatment and a relevant reduction of the total number of re-injections in RL&#xD;
      patients is expected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinal vein occlusion (RVO) is the second most common retinal vascular disease leading to&#xD;
      visual impairment. Main cause for visual impairment in CRVO (Central Retinal Vein Occlusion)&#xD;
      is macular edema (ME) while neovascularization of the retina and/or the anterior segment is&#xD;
      the most serious complication leading to vitreous hemorrhage, retinal detachment and&#xD;
      neovascular glaucoma. In serious cases loss of vision is imminent. To date, no causal&#xD;
      treatment has been proven to be effective in large trials. Intravitreal injections of drugs&#xD;
      that inhibit the vascular endothelial growth factor (VEGF) and other inflammatory factors are&#xD;
      the current treatments of choice for ME due to CRVO. Two different anti-VEGF drugs&#xD;
      (ranibizumab and aflibercept), and a biodegradable dexamethasone implant are approved by the&#xD;
      EMA (European Medicines Agency). Based on data from confirmatory studies anti-VEGF-drugs are&#xD;
      recommended as a treatment of first choice in patients with RVO. All intravitreal drugs&#xD;
      provide only a temporary effect with need for re-treatment for recurrences of ME. Mean number&#xD;
      of ranibizumab application needed in CRVO patients was found to be 7.4 to 10.2 injections in&#xD;
      12 months. A significant number of CRVO patients require treatment over several years. Need&#xD;
      for repetitive treatments and ophthalmic controls are a major burden for patients (and their&#xD;
      relatives who are required for driving the patients to ophthalmologists) despite of only few&#xD;
      adverse events and generally well-tolerated injections. Endophthalmitis is the most severe&#xD;
      ocular complication which can be eye-sight-threatening. The more injections are administered,&#xD;
      the higher is the cumulative risk of complications. Due to high costs (&gt;1000 € per injection)&#xD;
      treatment with repeated injections over years is of significant socio-economic importance,&#xD;
      too. Therefore, treatments concepts which would lead to permanent reduction of ME and/or&#xD;
      significantly reduce the number of re-injections over long-term periods are the major&#xD;
      currently unmet need in patients with RVO.&#xD;
&#xD;
      Until now, several studies evaluated the impact of the additional pan-retinal laser&#xD;
      photocoagulation in patients undergoing the anti-VEGF-treatment for the ME due to retinal&#xD;
      vein occlusions. However, most of the studies are limited by retrospective design, small&#xD;
      number of evaluated patients or lack of the randomization. None of the available prospective&#xD;
      randomized studies had sufficient power to finally clarify the benefit of the additional&#xD;
      laser treatment. Therefore, there is an unmet need for a large randomized, prospective,&#xD;
      multicentric trials.&#xD;
&#xD;
      The proposed study will be the first sufficiently powered trial evaluating the long-term&#xD;
      effect of targeted laser photocoagulation performed selectively (targeted) in peripheral&#xD;
      areas of non-perfusion in combination with standard anti-VEGF treatment (ranibizumab&#xD;
      injections) on the duration of the required intravitreal treatment over time period of 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>blinded BCVA assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy endpoint is the time to treatment success</measure>
    <time_frame>up-to 29 months</time_frame>
    <description>Time from randomisation until the date of last criteria-based intravitreal injection in case that thereafter a treatment-free period for (at least) 6 months was observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>Month 29</time_frame>
    <description>Best corrected visual acuity (BCVA) in number of ETDRS letters (Early Treatment of Diabetes Retinopathy Study) per visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central subfield thickness (CST)</measure>
    <time_frame>Month 29</time_frame>
    <description>Central subfield thickness (CST) measured by OCT per visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ranibizumab injections</measure>
    <time_frame>Month 29</time_frame>
    <description>Number of ranibizumab injections required until treatment success and up to the end of Observation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Development of neovascularization(s)</measure>
    <time_frame>Month 24</time_frame>
    <description>Proportion of subjects developing neovascularization(s) of retina, optic disc, and/or in anterior segment over the total period of observation.</description>
  </other_outcome>
  <other_outcome>
    <measure>The area of non-perfusion</measure>
    <time_frame>Month 24</time_frame>
    <description>The area of non-perfusion (assessed by FA) will be quantified as sum of all areas identified</description>
  </other_outcome>
  <other_outcome>
    <measure>Vessel density</measure>
    <time_frame>Month 24</time_frame>
    <description>Assessed by OCT-angiography, will be quantified by a metric measure with the range [0;1]</description>
  </other_outcome>
  <other_outcome>
    <measure>Potential visual field loss</measure>
    <time_frame>Month 4 and Month 24</time_frame>
    <description>The change between the two timepoints (Months 4 and 24) per arm will be used to characterize the both groups and be compared between treatment arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>The number of laser treatments and the laser spots given in the experimental group (RL-arm).</measure>
    <time_frame>Month 24</time_frame>
    <description>The number of visits with applied laser treatment and the laser spots applied in the experimental group (RL-arm) will be counted for descriptive reasons and be compared between treatment arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Health-related quality of life (QoL): Visual Function Questionnaire VFQ25</measure>
    <time_frame>Baseline, Month 12 and Month 24</time_frame>
    <description>Measured by the Visual Function Questionnaire VFQ25</description>
  </other_outcome>
  <other_outcome>
    <measure>Areal of foveal avascular zone</measure>
    <time_frame>Month 24</time_frame>
    <description>Area of the foveal avascular zone (FAZ, assessed by OCT-angiography, will be quantified in [mmm²])</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Central Retinal Vein Occlusion With Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ranibizumab+Laser-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranibizumab injections and additional targeted laser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab-arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only Ranibizumab injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab Injection</intervention_name>
    <description>initial three injections of Ranibizumab - afterwards pro re nata monthly</description>
    <arm_group_label>Ranibizumab+Laser-arm</arm_group_label>
    <arm_group_label>Ranibizumab-arm</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser photocoagulation</intervention_name>
    <description>Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times</description>
    <arm_group_label>Ranibizumab+Laser-arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of macular edema due to central retinal vein occlusion foveal thickness &gt;&#xD;
             250 μm (measured by OCT)&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Written informed consent of the patient&#xD;
&#xD;
          -  BCVA score in the study eye between 24 letters (20/320) and 78 letters (20/25)&#xD;
             measured in ETDRS chart&#xD;
&#xD;
          -  History of CRVO no longer than 6 months&#xD;
&#xD;
          -  Presence of capillary non-perfusion in peripheral retina larger than 5 disc areas&#xD;
             documented in ultra wide-field fluorescein angiography&#xD;
&#xD;
          -  Ability and willingness to attend all scheduled visits and assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CRVO with ischemic maculopathy defined as diameter of the foveolar avascular zone&#xD;
             larger than 2 optic disc diameters&#xD;
&#xD;
          -  Macular edema due to another etiology than retinal vein occlusion (e.g. diabetic&#xD;
             maculopathy, uveitis, age related macular degeneration, Irvine-Gass syndrome)&#xD;
&#xD;
          -  History of idiopathic central serous chorioretinopathy&#xD;
&#xD;
          -  Presence of vitreoretinal interface disease (e.g. vitreomacular traction, epiretinal&#xD;
             membrane), either on clinical examination or in OCT&#xD;
&#xD;
          -  An eye that, in the investigator's opinion, would not benefit from resolution of&#xD;
             macular edema, such as eyes with foveal atrophy, dense pigmentary changes, or dense&#xD;
             subfoveal hard exudates&#xD;
&#xD;
          -  Aphakia in the study eye&#xD;
&#xD;
          -  Scatter laser photocoagulation or macular photocoagulation in the study eye prior to&#xD;
             study entry&#xD;
&#xD;
          -  Intraocular or periocular injection of steroids in the study eye prior to study entry&#xD;
&#xD;
          -  Previous use of an anti-VEGF drug in the study eye&#xD;
&#xD;
          -  Cataract surgery or any other intraocular surgery in the study eye within 3 months&#xD;
             prior to study entry&#xD;
&#xD;
          -  Uncontrolled glaucoma (defined as intraocular pressure ≥ 30 mm Hg despite treatment&#xD;
             with maximal anti-glaucoma medications)&#xD;
&#xD;
          -  History of stroke, myocardial infarction, transient ischemic attacks within 3 months&#xD;
             prior to the study&#xD;
&#xD;
          -  Pregnancy (positive urine pregnancy test) or lactation&#xD;
&#xD;
          -  The presence of active malignancy, including lymphoproliferative disorders.&#xD;
&#xD;
          -  History of allergy to fluorescein or any component of the ranibizumab formulation&#xD;
&#xD;
          -  Active intraocular infection&#xD;
&#xD;
          -  Participation in another simultaneous interventional medical investigation or trial&#xD;
&#xD;
          -  Women with child bearing potency without effective contraception (i. e. implants,&#xD;
             injectables, combined oral contraceptives, some IUDs or vasectomised partner) during&#xD;
             the conduct of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matus Rehak, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Department of Ophthalmology University Hospital of Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matus Rehak, Professor</last_name>
    <phone>0049 341 97 21 650</phone>
    <email>matus.rehak@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marizel Schwarzkopf, Dr.</last_name>
    <phone>0049 341 97 16 254</phone>
    <email>marizel.schwarzkopf@zks.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden Klinik und Polyklinik für Augenheilkunde</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Sandner, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Klinik für Augenheilkunde Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hansjürgen Agostini, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover MHH Universitätsklinik für Augenheilkunde</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amelie Pielen, PD. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Leipzig Department of Ophthalmology</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matus Rehak, Prof. MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen Augenklinik</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars-Olof Hattenbach, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg Klinik für Augenheilkunde</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Walter Sekundo, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augenzentrum am St. Franziskus-Hospital Münster</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg Spital, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Klinik für Augenheilkunde</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Eter, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Matus Rehak, MD, Ph.D.</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

